Moreover, overexpression of MAEA in mouse hepatocytes has been shown to reduce hepatic gluconeogenesis, highlighting its potential as a therapeutic target for type 2 diabetes treatment [34]. The gene discussed is MAEA; the disease is type 2 diabetes mellitus.